76 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
7 May 24
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
8:01am
the efficacy and safety of the Nanobody® sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key … , with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).
In an earlier Phase 1 trial in patients
8-K
EX-99.2
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
in psoriasis 1 Rapid and durable skin clearance (PASI 100) with no unexpected safety findings As a Nanobody ® , sonelokimab (SLK) is designed to penetrate … Serious infection 0 0 0 0 0 0 MACE 0 0 0 0 0 0 Liver AST/ALT 5x ULN 3 Safety: no notable signals, a favorable benefit - risk profile in PsA Source
8-K
EX-99.1
p8xgzmcxkl
11 Mar 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
dlguzr4mq 7izafxxac
29 Feb 24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
8:03am
8-K
EX-99.1
tro0gr xpl8ofiow4pb
26 Feb 24
Regulation FD Disclosure
9:00am
8-K
EX-99.1
624blubpusoof7mnku
14 Nov 23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.2
4v6h7u
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
da26vkl0
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
oq6t7v
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-99.1
sb583th13g8ktruo60aw
16 Oct 23
Regulation FD Disclosure
6:16am
8-K
b5euhivl
16 Oct 23
Regulation FD Disclosure
6:16am
8-K
EX-99.1
jz27oimvfujo6uk6g
10 Aug 23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
8:15am